/ /

  • linkedin
  • Increase Font
  • Sharebar

    New strategies to assess the risk of diabetes-related vision loss

    ODs must go outside the lines of traditional eye care

     

    References

    1. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. JAMA. 2015 Sep 8;314(10):1021-1029.

    2. Centers for Disease Control and Prevention. Diabetic Retinopathy Fact Sheet. Available https://www.cdc.gov/visionhealth/pdf/factsheet.pdf. Accessed 5/16/17.

    3. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, Ranganathan G, Wirostko B, Pleil A, Mitchell P. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care. 2009 Dec;32(12):2307-13.

    4. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Visi (Lond). 2015 Sep 30;2:17.

    5. Menke A, Casagrande S, Geiss L, Cowie CC.Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. JAMA. 2015 Sep 8;314(10):1021-9.

    6. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-1686.

    7. Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016 May;44(4):260-77.

    8. Frank RN. Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol. 2015 Apr-Jun;22(2):151-6.

    9. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007 Aug 22;298(8):902-16.

    10. Ajlan RS, Silva PS, Sun JK. Vascular Endothelial Growth Factor and Diabetic Retinal Disease. Semin Ophthalmol. 2016;31(1-2):40-8.

    11. Virgili G, Menchini F, Murro V, Peluso E, Rosa F, Casazza G. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008081.

    12. Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, Pesudovs K, Price H, White RA, Wong TY, Resnikoff S, Taylor HR; Vision Loss Expert Group of the Global Burden of Disease Study. Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010. Diabetes Care. 2016 Sep;39(9):1643-9.

    13. Nam S, Chesla C, Stotts NA, et al. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011 Jul;93(1):1-9.

    14. Shao J, Zaro JL, Shen WC. Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics. Tissue Barriers. 2016 Mar 4;4(2):e1156804.

    15. Chous AP. Worldwide diabetes epidemic approaches half a billion. Optometry Times. Available at: http://optometrytimes.modernmedicine.com/optometrytimes/news/worldwide-diabetes-epidemic-approaches-half-billion. Accessed 5/15/17.

    16. Fisher MD, Rajput Y, Gu T, Singer JR, Marshall AR, Ryu S, Barron J, MacLean C. Evaluating Adherence to Dilated Eye Examination Recommendations Among Patients with Diabetes, Combined with Patient and Provider Perspectives. Am Health Drug Benefits. 2016 Oct;9(7):385-393.

    17. Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014 Sep 6;11(11):1185-200.

    18. Agouridis AP, Kostapanos MS, Elisaf MS. Statins and their increased risk of inducing diabetes. Expert Opin Drug Saf. 2015;14(12):1835-44.

    19. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007 Jan 20;369(9557):201-7.

    20. McDonnell SL, Baggerly LL, French CB, Heaney RP, Gorham ED, Holick MF, Scragg R, Garland CF. Incidence rate of type 2 diabetes is >50% lower in GrassrootsHealth cohort with median serum 25-hydroxyvitamin D of 41 ng/ml than in NHANES cohort with median of 22 ng/ml. J Steroid Biochem Mol Biol. 2016 Jan;155(Pt B):239-44.

    21. Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World J Diabetes. 2015 Feb 15;6(1):92-108.

    22. Cahn F, Burd J, Ignotz K, Mishra S. Measurement of Lens Autofluorescence Can Distinguish Subjects With Diabetes From Those Without. J Diabetes Sci Technol. 2014 Jan;8(1):43-49.

    23. Gelb KM, Richer SP, Zimmer CN, Sherman J, Gold JM. Retinal multispectral imaging of ‘sub-clinical’ capillary microaneurysms in non-diabetics correlates with insulin resistance. Diabesity. 2016 Jul;2(3):19-25.

    24. Hu BJ, Hu YN, Lin S, Ma WJ, Li XR. Application of Lutein and Zeaxanthin in nonproliferative diabetic retinopathy. Int J Ophthalmol. 2011;4(3):303-306.

    25. Scanlon G1, Connell P, Ratzlaff M, Foerg B, McCartney D, Murphy A, OʼConnor K, Loughman J. Macular pigment optical density is lower in type 2 diabetes, compared with type 1 diabetes and normal controls. Retina. 2015 Sep;35(9):1808-16.

    26. Lima VC, Rosen RB, Farah M. Macular pigment in retinal health and disease. Int J Retina Vitreous. 2016 Aug 15;2:19.

    27. Chen X, Rong SS, Xu Q, Tang FY, Liu Y, Gu H, Tam PO, Chen LJ, Brelén ME, Pang CP, Zhao C. Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis. PLoS One. 2014 Sep 19;9(9):e108196.

    28. American Diabetes Association. Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers. Clin Diabetes. 2016 Jan; 34(1): 3–21.

    29. Giacco F, Du X1, Carratú A, Gerfen GJ, D'Apolito M, Giardino I, Rasola A, Marin O, Divakaruni AS, Murphy AN, Shah MS, Brownlee M. GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop. Diabetes. 2015 Sep;64(9):3273-3284.

    30. Wang B, Wang F, Zhang Y, Zhao SH, Zhao WJ, Yan SL, Wang YG.

    Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015 Apr;3(4):263-74.

    31. Sharma N, Ooi JL, Ong J, Newman D. The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review. Aust Fam Physician. 2015 Jun;44(6):367-70.

    32. Gualtieri M, Bandeira M, Hamer RD, Damico FM, Moura AL, Ventura DF. Contrast sensitivity mediated by inferred magno- and parvocellular pathways in type 2 diabetics with and without nonproliferative retinopathy. Invest Ophthalmol Vis Sci. 2011 Feb 28;52(2):1151-5.

    33. Utku D, Atmaca LS. Farnsworth-Munsell 100-hue test for patients with diabetes mellitus. Ann Ophthalmol. 1992 Jun;24:205–8.

    34. Pinilla I, Ferreras A, Idoipe M, Sanchez-Cano AI, Perez-Garcia D, Herrera LX, Pinilla MJ, Abecia E. Changes in frequency-doubling perimetry in patients with type I diabetes prior to retinopathy. Biomed Res Int. 2013;2013:341269.

    35. Shrestha GS, Kaiti R. Visual functions and disability in diabetic retinopathy patients. J Optom. 2014 Jan-Mar;7(1):37-43. 

    36. Kowluru RA, Zhong Q. Beyond AREDS: Is There a Place for Antioxidant Therapy in the Prevention/Treatment of Eye Disease? Invest Ophthalmol Vis Sci. 2011 Nov 7;52(12):8665-71.

    37. Chous AP, Richer SP, Gerson JD, Kowluru RA. The Diabetes Visual Function Supplement Study (DiVFuSS). Br J Ophthalmol. 2016 Feb;100(2):227-234.

    38. Kowluru RA, Zhong Q, Santos JM, Thandampallayam M, Putt D, Gierhart DL. Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutr Metab (Lond). 2014 Jan 30;11(1):8.

    39. Gao SS, Jia Y, Zhang M, Su JP, Liu G, Hwang TS, Bailey ST, Huang D. Optical Coherence Tomography Angiography. Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT27-36.

    Read more from Dr. Chous here

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available